Entera Bio Ltd. (ENTX) Financials
ENTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 19.5 million | 12.2 million |
| March 31, 2026 | 13.1 million | 2.4 million |
| Dec. 31, 2025 | 16.0 million | 2.9 million |
| Sept. 30, 2025 | 17.4 million | 2.2 million |
ENTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -3.5 million | 624000 |
| March 31, 2026 | -3.1 million | 672000 |
| Dec. 31, 2025 | -2.1 million | 710000 |
| Sept. 30, 2025 | -2.8 million | 927000 |
ENTX Net Income
No data available :(
ENTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 11.3 million | - | 425000 |
| March 31, 2026 | 4.1 million | 263000 | 185000 |
| Dec. 31, 2025 | 7.1 million | 260000 | 230000 |
| Sept. 30, 2025 | 8.6 million | 41000 | 170000 |
ENTX Shares Outstanding
ENTX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 3000 | 3.2 million | 1.4 million | - |
| March 31, 2026 | - | 2.2 million | 1.3 million | - |
| Dec. 31, 2025 | 29836 | 1.7 million | 1.3 million | - |
| Sept. 30, 2025 | 46477 | 1.6 million | 1.6 million | - |
ENTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 7000 |
| Dec. 31, 2025 | - | 7000 |
| Sept. 30, 2025 | - | 8000 |
ENTX
Price: $2.77
52 week price:
Earnings Per Share: -0.35 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: Israel
Volume: 1891
Market Capitalization: 124.7 million